Legal Aspects of the Balance of Interests: Pharmaceutical Companies Innovators and Generic Manufacturers

The paper deals with the problems of entering the market of generic drugs in the light of protecting the interests of copyright holder-originators. It is emphasized that the main method of protection lies in the area of intellectual rights. The protection of patent rights by companies that are copyright holders of innovative medicines comes out on top. Attention is drawn to issues related to the data exclusivity regime that are especially important in the context of establishing a balance of interests not only between the copyright holders of original medicines and generic manufacturing companies, but also between representatives of the medical community. The paper considers individual rules of special normative legal acts regulating relations related to the circulation of medicines in Russia and abroad. The author draws attention to the fact that there is some terminological ambiguity, which creates difficulties in the implementation of legal regulation. Possible restrictions on the rights of companies that put into circulation generic medicines should act as a certain guarantor in the implementation of the proper legal mechanisms for the protection of the results of intellectual activity in the pharmaceutical sector and contribute to the stimulation of innovation.

1. Gavrilov E. P. Pravovaya ohrana lekarstvennyh sredstv: chto neobhodimo izmenit’? // Patenty i licenzii. — 2018. — № 4.

2. Davydova K. S. Sovershenstvovanie sistemy ekspertizy vosproizvedennyh lekarstvennyh sredstv pri ih gosudarstvennoj registracii : avtoref. dis. … d-ra med. nauk. — M., 2011.

3. Dan’kov A. A. Obespechenie balansa publichnyh i chastnyh interesov v sfere pravosudiya : dis. … kand. yurid. nauk. — M., 2014.

4. Litvinova E. V., Posylkina O. V. Sravnitel’nyj analiz patentnogo zakonodatel’stva Ukrainy, Rossijskoj Federacii, Evropy i SShA v sfere farmacii // Nauchnye vedomosti. Seriya : Medicina. Farmaciya. — 2014. — № 1 (175). — Vyp. 25.

5. Prihod’ko M. A. Mezhdunarodnoe patentovanie farmacevticheskih produktov : avtoref. dis. … kand. yurid. nauk. — M., 2018.

6. Ulumbekova G. E., Kalashnikova A. V. Analiz rynka lekarstvennyh preparatov v RF // Vestnik VShOUZ. — 2018. — № 2.

7. Shahnazarov B. A. Modernizaciya prava intellektual’noj sobstvennosti RF v usloviyah chlenstva v VTO // Lex russica (Russkij zakon). — 2013. — № 3. — S. 295–296.

8. Shahnazarov B. A. Pravovoe regulirovanie otnoshenij po transgranichnoj peredache prav na ob"ekty promyshlennoj sobstvennosti : avtoref. dis. … kand. yurid. nauk : 12.00.03. — M., 2010.

9. Pei-kan Yang. Patent Term Extension for Pharmaceutical Products in Free Trade Agreements and Policy Options for Mitigation of Health Implications // Manchester Journal of International Economic Law. — 2020. — Vol. 17.

10. Proteesh Rana, Vandana Roy. Generic Medicines: Issues and relevance for global health // Fundamental & Clinical Pharmacology. 2015.

11. Haffajee R. L. and Frank R. G. Generic Drug Policy and Suboxone to Treat Opioid Use Disorder // The Journal of Law, Medicine & Ethics. — 47 S4. 2019. — P. 43–53.

12. Srividhya Ravagan. The Drug Debate: Data Exclusivity is the New Way to Delay Generics // Connecticut Law Review Online. Vol. 50:2.

13. Shapiro Z. E., Pan A., James K., Wright M. S. & Fins J. J. Nothing generic about it: promoting therapeutic access by overcoming regulatory and legal barriers to robust generic medical device market // North Carolina Law Abstract. — 98 N.C. L. Rev. — 595. — 2020.